Pradaxa was approved in October 2010 as a blood thinning medication used to reduce the risk of stroke and blood clots in patients with non-valvular atrial fibrillation (AF).

On October 6, 2011, the Institute for Safe Medication Practices, (ISMP), reported that after a rapid launch of the medication, hundreds of adverse events involving hemorrhages had been filed with the FDA within weeks of approval

Then on November 18, 2011 the European Medicines Agency (EMA), Europe’s FDA equivalent, reported a worldwide total of 256 fatal bleed incidents involving dabigatran, the active ingredient in Pradaxa.

On December 7, 2011, the U. S. Food and Drug Administration (FDA) issued a Safety Communication reporting that it was investigating reports of serious and fatal bleeds in patients taking Pradaxa.

If you, or a loved one, have suffered a serious Pradaxa side effects such as fatal hemorrhage, such as a Pradaxa brain bleed or a gastrointestinal bleed, while or shortly after taking Pradaxa, you may be entitled to compensation.

Contact the experienced Pradaxa lawyers of Ennis & Ennis, P.A. today by calling toll free (800)856-6405 or by completing the online form at www.ennislaw.com for a free, confidential consultation.